The Pharma Podcast

COVID-19 Special Edition – Canadian Access to Future Coronovirus Treatment – Canadian Regulatory Framework

April 27, 2020 Nathaniel Lipkus, Intellectual Property Litigator, and Partner at Osler, Hoskin & Harcourt LLP in Toronto Season 1 Episode 5
The Pharma Podcast
COVID-19 Special Edition – Canadian Access to Future Coronovirus Treatment – Canadian Regulatory Framework
Show Notes

In this episode I spoke with Nathaniel Lipkus, intellectual property litigator, and partner at Osler, Hoskin & Harcourt LLP.

Nate is a legal expert on patent and regulatory issues facing pharmaceutical and biotechnology companies. 

Nate has also published extensively on topics pertaining to Canada’s Patent Act . Nate  recently wrote an article for the Globe and Mail exploring today’s topic.   

In this episode, Nate provides insight on Canada's regulatory framework and how it can assist Canadian access to new therapeutics to the novel coronavirus.  Specifically, we explore the COVID-19 Emergency Response Act (Bill C-13) and its provisions. 

We also explore Canada’s industrial capability to meet future demand to treatment.

CONTACT INFORMATION

nlipkus@osler.com